Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab
Junko Tanizaki(Kindai University Sakai Hospital), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Kimio Yonesaka(Kindai University), Koji Haratani(Dana-Farber Cancer Institute), Akihiko Ito(Kobe University), Hiroyasu Kaneda(Osaka City University), Masayuki Takeda(Kindai University), Kaoru Tanaka(Kindai University), Yasushi Nakamura(Kindai University), Keita Kudo(Osaka Minami Medical Center), Yasutaka Chiba(Kindai University Hospital), Yoshikazu Hasegawa(Izumi City General Hospital), Hidetoshi Hayashi(Kindai University)
Cited by 227
Related Papers
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
|Journal of Clinical Oncology|2011|1.6k